VivoSeq
Metabolic & Endocrine

Overweight or Obese

4

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Overweight or Obese is an early-stage landscape with 4 programs across 5 companies. The most active players are Alveus Therapeutics, Inc., Carmot Therapeutics, Inc., Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Alveus Therapeutics, Inc.

1 program

Phase 1C

Carmot Therapeutics, Inc.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Pfizer logo

Pfizer

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Terminated1 · 17%
Recruiting1 · 17%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes
Recruiting·AAlveus Therapeutics, Inc.·Phase 1·NCT07399678·180 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Active, not recruiting·CCarmot Therapeutics, Inc.·Phase 2·NCT06628362·447 enrolled
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
Not yet recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT07658560·200 enrolled
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
Completed·Pfizer logoPfizer·Phase 1·NCT05745701·16 enrolled
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05815680·48 enrolled
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
Terminated·Pfizer logoPfizer·Phase 1·NCT05788328·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)